How Much Does Psychedelic-Assisted Therapy Cost? A 2026 Price Guide
A detailed breakdown of what ketamine, psilocybin, and other psychedelic-assisted therapies cost in 2026, including insurance coverage, program structures, and options to reduce out-of-pocket expenses.
Psychedelic-assisted therapy is no longer the fringe of mental health treatment. Ketamine is FDA-approved, esketamine is covered by many insurance plans, and licensed psilocybin service centers have opened in Oregon and Colorado. But for most people weighing these options, cost is one of the first — and biggest — practical questions.
The short answer: psychedelic-assisted therapies carry a significant price tag. A full ketamine program runs $2,400 to $4,800 out of pocket. Oregon psilocybin services typically cost $2,000 to $6,500 per complete program. These numbers are not obstacles to hide but realities to plan around — and there are meaningful ways to reduce costs, including insurance coverage and clinical trial enrollment.
This guide breaks down the pricing landscape for every major form of psychedelic-assisted therapy available in 2026, explains what affects cost, and identifies practical options for people who cannot pay market rate.
1 in 3
What Counts as Psychedelic-Assisted Therapy?
"Psychedelic-assisted therapy" covers several distinct treatments that differ in legal status, clinical setting, cost structure, and evidence base:
- Ketamine and esketamine — The only FDA-approved psychedelic-category treatments. Ketamine is an off-label anesthetic used at ketamine clinics; esketamine (Spravato) is an FDA-approved nasal spray.
- Psilocybin therapy — Legal in Oregon and Colorado through regulated service programs; still in clinical trials nationally.
- MDMA-assisted therapy — Remains under research review following the FDA's 2024 Complete Response Letter; not yet commercially available.
- Other compounds — LSD, DMT, and ibogaine are being studied but remain in early-phase trials with no approved clinical route in the U.S.
This guide focuses on the treatments you can actually access and pay for today.
Ketamine Infusion Therapy: Cost Breakdown
Intravenous (IV) ketamine infusions are the most established and widely available form of psychedelic-assisted treatment. Offered at dedicated ketamine clinics and some anesthesiology practices nationwide, ketamine infusions involve a series of medically supervised sessions in which the drug is delivered slowly through a vein while a clinician monitors your response.
What You Pay Per Session
IV ketamine infusion costs vary by location, provider type, and whether psychotherapy is included:
| Setting | Cost Per Session |
|---|---|
| Standalone ketamine clinic | $400 – $800 |
| Anesthesiologist-led practice | $500 – $950 |
| Integrative psychiatry program | $600 – $1,200 |
A standard initial treatment course is six sessions over two to three weeks. That puts the typical out-of-pocket cost for a full initial course at $2,400 to $4,800.
Maintenance infusions, which many people need every four to eight weeks to sustain benefit, add $400 to $800 per session on an ongoing basis.
Add-On Costs to Anticipate
The infusion itself is only part of the expense. Most reputable programs include:
- Intake evaluation and medical clearance: $150 – $300
- Integration therapy (a separate therapist helping you process the experience): $100 – $250 per session
- Monthly maintenance infusions (if needed): $400 – $800 each
When you factor in integration therapy and a year of periodic maintenance, annual costs for ongoing ketamine treatment can range from $5,000 to $12,000.
Does Insurance Cover Ketamine Infusions?
Generally, no. IV ketamine is used off-label for depression, anxiety, and PTSD, and most commercial insurers do not yet cover it. Medicare and Medicaid do not cover IV ketamine infusions for psychiatric indications.
Some insurers will reimburse ketamine when it is used for approved anesthetic purposes (such as pain management), but the mental health application remains largely an out-of-pocket expense.
What to try: Ask your clinic for a superbill and submit it to your insurer anyway. A small percentage of plans cover ketamine on a case-by-case basis, particularly for treatment-resistant depression with documented prior treatment failures.
Esketamine (Spravato): Cost and Insurance
Esketamine — sold as Spravato — is chemically related to ketamine but represents an entirely different cost picture. Because it carries FDA approval for treatment-resistant depression and major depressive disorder with suicidal ideation, it is the psychedelic-category treatment most likely to be covered by insurance.
How Esketamine Is Administered
Spravato is a nasal spray self-administered under clinical supervision in a certified healthcare facility. Patients must remain at the facility for at least two hours after each dose. The standard schedule is:
- Induction phase: Twice weekly for four weeks
- Maintenance phase: Once weekly, then once every two weeks
What Spravato Costs Without Insurance
Without insurance, a single Spravato session costs approximately $800 to $1,000 for the drug alone, plus the facility administration fee. A full eight-session induction course could cost $6,400 to $8,000 out of pocket.
What Spravato Costs With Insurance
Here the picture is far better. Because Spravato is FDA-approved for specific indications:
- Commercial insurance (most employer plans, ACA marketplace plans): Covered for qualifying diagnoses with prior authorization. Copays typically range from $10 to $50 per session with proper coverage.
- Medicare Part D: Covers Spravato for approved indications.
- Medicaid: Coverage varies by state; many state Medicaid programs do cover it.
The manufacturer (Johnson & Johnson) also operates a patient assistance program. Eligible patients may pay as little as $10 per session.
$10–$50
To access insurance coverage: Your psychiatrist must document that you have tried and failed at least two standard antidepressants. Prior authorization is required in almost every case. Work with a psychiatrist — not just a primary care provider — to navigate the approval process.
Psilocybin Therapy: Oregon and Colorado Costs
Oregon became the first U.S. state to open licensed psilocybin service centers in 2023 under Measure 109. Colorado is following a similar path under Proposition 122. If you live in or can travel to one of these states, psilocybin therapy through a licensed facilitator is legal, structured, and increasingly available.
What a Psilocybin Program Includes
Licensed psilocybin programs are not just a "trip with a guide." They involve three phases:
- Preparation sessions (two to four hours): Getting to know your facilitator, discussing intentions and history, completing health screening
- Psilocybin session (four to eight hours): The supervised experience itself, typically in a comfortable, clinical-adjacent setting
- Integration sessions (one to three hours): Processing the experience and translating insights into lasting change
Cost Range for Psilocybin Services
Oregon facilitators and service centers set their own prices. Based on early market data:
| Program Component | Cost Range |
|---|---|
| Preparation (2–4 sessions) | $300 – $800 |
| Psilocybin session | $800 – $3,000 |
| Integration (1–3 sessions) | $200 – $600 |
| Complete program total | $2,000 – $6,500 |
Higher-end retreat-style programs, often marketed as wellness experiences, can run $7,000 to $15,000, though these are not medical programs and lack clinical oversight.
Insurance Coverage for Psilocybin
No U.S. insurer currently covers psilocybin services. Because psilocybin remains a Schedule I substance federally, coverage is not expected in the near term even in states where it is legal. Psilocybin programs are entirely out-of-pocket costs.
Some Oregon service centers offer sliding-scale fees and community programs to reduce access barriers. Ask directly about financial assistance when you contact a center.
MDMA-Assisted Therapy: Where Things Stand
The FDA issued a Complete Response Letter for MDMA-assisted therapy for PTSD in August 2024, citing concerns about trial design and data reliability. As of 2026, MDMA-assisted therapy is not commercially available in the U.S.
For people with PTSD or treatment-resistant conditions, MDMA research is still ongoing. You may be able to access it through clinical trials without paying for the drug itself — see the section below on clinical trials.
Clinical Trials: A Path to Free Access
If you cannot afford standard pricing, clinical trials offer a legitimate and potentially transformative alternative. Participants in FDA-regulated clinical trials receive the investigational treatment at no cost, along with close medical monitoring.
Active trials as of 2026 are studying:
- Psilocybin for depression, OCD, addiction, and end-of-life anxiety
- MDMA for PTSD and social anxiety in autistic adults
- Ketamine protocols for chronic pain and borderline personality disorder
How to find trials: Search clinicaltrials.gov with terms like "psilocybin depression" or "MDMA PTSD." You can filter by location, phase, and recruitment status.
Be realistic about eligibility — most trials have specific inclusion and exclusion criteria — but for motivated candidates with qualifying diagnoses, this route is worth pursuing.
200+
Comparing Costs: Psychedelic Therapy vs. Traditional Treatment
How does psychedelic-assisted therapy compare to conventional approaches?
| Treatment | Typical Total Cost | Insurance Coverage |
|---|---|---|
| CBT (16 sessions) | $1,600 – $4,800 | Usually yes |
| SSRI medication (1 year) | $120 – $1,200 | Usually yes |
| IV ketamine program (6 sessions) | $2,400 – $4,800 | Rarely |
| Esketamine induction (8 sessions) | $80 – $400 copay | Often yes |
| Psilocybin program (Oregon) | $2,000 – $6,500 | Never |
Cognitive Behavioral Therapy (CBT) and medication are substantially cheaper when covered by insurance, and they remain first-line treatments for most people. Psychedelic-assisted therapies tend to be most cost-effective for people who have already tried conventional approaches without adequate benefit.
Ways to Reduce Out-of-Pocket Costs
If the price is a barrier, here are practical paths forward:
-
Pursue esketamine through insurance. If you have documented treatment-resistant depression, work with a board-certified psychiatrist to meet prior authorization requirements for Spravato. The cost difference between covered and uncovered is enormous.
-
Enroll in a clinical trial. If your condition qualifies, a trial can provide access to the cutting-edge treatment entirely free.
-
Ask about sliding-scale pricing. A growing number of psilocybin service centers in Oregon have community access programs. Some ketamine clinics offer payment plans or income-based discounts.
-
Use an HSA or FSA. Ketamine infusions for mental health purposes may qualify as an eligible medical expense under a Health Savings Account (HSA) or Flexible Spending Account (FSA). Consult your plan administrator to confirm.
-
Prioritize integration therapy. If you can access a psilocybin or ketamine experience at a lower cost, pairing it with ongoing integration therapy — with a therapist who specializes in psychedelic integration — can help maximize the benefit of a single session, potentially reducing the need for repeat treatments.
Frequently Asked Questions
Rarely for intravenous ketamine used for psychiatric purposes, since it is administered off-label. However, esketamine (Spravato), which is FDA-approved for treatment-resistant depression, is covered by many commercial plans, Medicare, and some Medicaid programs when prior authorization criteria are met.
A standard six-session IV ketamine induction course typically costs $2,400 to $4,800 out of pocket. Add integration therapy sessions and periodic maintenance infusions, and annual costs can reach $5,000 to $12,000 for people who need ongoing treatment.
No. Psilocybin remains federally classified as Schedule I, and no U.S. insurer currently covers psilocybin services. Even in Oregon and Colorado where it is state-legal, you will pay entirely out of pocket — typically $2,000 to $6,500 for a complete program.
Potentially, yes. Ketamine infusions for mental health treatment may qualify as an eligible medical expense under a Health Savings Account or Flexible Spending Account. Rules vary by plan, so contact your HSA or FSA administrator before paying to confirm eligibility and get proper documentation from your provider.
As of 2026, MDMA-assisted therapy is not commercially available in the United States following the FDA's 2024 Complete Response Letter. The primary legitimate route is enrollment in a clinical trial. Search clinicaltrials.gov for active MDMA studies, particularly for PTSD, and contact the research teams to ask about eligibility.
For people who have tried and failed multiple conventional treatments, the clinical evidence — particularly for ketamine in treatment-resistant depression and psilocybin in major depression — suggests meaningful benefit for a significant proportion of patients. However, outcomes vary, and these treatments are not universally effective. The cost-effectiveness calculation is most favorable when conventional options have been exhausted.
Yes. Clinical trials offer access to investigational treatments including psilocybin and MDMA at no cost to participants. Esketamine through insurance can reduce costs dramatically for qualifying patients. Some Oregon psilocybin service centers offer sliding-scale or community-access pricing. Reaching out directly to providers to ask about financial assistance is always worth doing.
Look for clinics led by board-certified physicians (anesthesiologists, psychiatrists, or emergency medicine specialists) who perform medical screening before treatment. Ask for a complete fee schedule upfront, including any charges for intake, monitoring, and post-session care. Be cautious of clinics that do not require a referral or medical history, do not include psychiatric integration support, or make exaggerated promises about outcomes.
Explore Your Treatment Options
Psychedelic-assisted therapies are one part of a broader landscape of mental health treatments. If you are looking for what is available and covered for your specific situation, start with an evidence-based overview.
Read the Full Psychedelic Therapy Guide